Sexual wellness
A pilot study of the role of intracavernous injection of vasoactive intestinal peptide (VIP) and phentolamine mesylate in the treatment of erectile dysfunction
Sandhu D, Curless E, Dean J. · Int J Impot Res · 1999
PMID: 8981173 · DOI: 10.1038/sj.ijir.3900249
Summary
Pilot clinical study of intracavernous VIP combined with phentolamine mesylate in men with erectile dysfunction. Endpoints: erectile response, partner-reported satisfaction, adverse events.
Citation hosted by NCBI. We link to the source so the researcher can read the abstract, full text, or references-cited list directly.
More Sexual wellness citations
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 TrialsObstet Gynecol · 2019
- Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire DisorderObstet Gynecol · 2019
- Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunctionInt J Impot Res · 2004